.STUDY HIGHLIGHT.06 August 2024.
A sizable randomized regulated trial with cisgender ladies highlights the challenges of faithfulness to a regular oral preexposure prevention program and also shows that twice-yearly injection of lenacapavir may keep successful HIV protection levels over 6 months.